OrthoPediatrics Corp. (NASDAQ:KIDS) Receives $23.89 Average Target Price from Brokerages

OrthoPediatrics Corp. (NASDAQ:KIDS) has been given an average rating of “Moderate Buy” by the eleven ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $23.8889.

KIDS has been the subject of several research analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $23.00 target price on shares of OrthoPediatrics in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Needham & Company LLC decreased their target price on OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Canaccord Genuity Group began coverage on OrthoPediatrics in a research note on Wednesday, December 10th. They issued a “buy” rating and a $24.00 target price for the company. Finally, Wall Street Zen raised OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th.

OrthoPediatrics Price Performance

KIDS opened at $16.71 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.52 and a current ratio of 7.40. The stock has a market capitalization of $419.09 million, a PE ratio of -8.57 and a beta of 1.12. The stock’s 50 day moving average price is $17.88 and its 200-day moving average price is $18.45. OrthoPediatrics has a 52-week low of $15.28 and a 52-week high of $26.40.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of KIDS. Russell Investments Group Ltd. raised its stake in OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after buying an additional 1,139 shares during the last quarter. Caption Management LLC bought a new position in shares of OrthoPediatrics during the third quarter valued at $54,000. BNP Paribas Financial Markets raised its position in shares of OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares during the last quarter. FourThought Financial Partners LLC bought a new position in OrthoPediatrics in the 4th quarter worth about $197,000. Finally, Los Angeles Capital Management LLC purchased a new stake in OrthoPediatrics during the 2nd quarter valued at about $220,000. 69.05% of the stock is owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.